Shuttle Pharmaceuticals Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
SHPH$5.59+10.8%Stored close · as of Nov 6, 2026
Contents
Item 1. Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024
Condensed Consolidated Balance Sheets
| June 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $4,817,672 | $1,920,144 |
| Prepaid expenses | 374,245 | 290,773 |
| Total current assets | 5,191,917 | 2,210,917 |
| Property and equipment, net | 19,335 | 19,364 |
| Deferred financing costs | 48,487 | — |
| Operating lease right-of-use asset | 244,690 | 276,009 |
| Total Assets | 5,504,429 | 2,506,290 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $1,174,374 | $596,600 |
| Accrued interest payable - related parties | 590 | 1,785 |
| Notes payable to related parties | 65,326 | 190,270 |
| Convertible notes payable, net - fair value option, related parties | 127,689 | 206,085 |
| Convertible notes payable, net - fair value option | 252,938 | 478,120 |
| Operating lease liability | 71,869 | 60,909 |
| Total current liabilities | 1,692,786 | 1,533,769 |
| Derivative liability | 10,965 | 25,281 |
| Operating lease liability non-current | 195,159 | 238,088 |
| Total Liabilities | 1,898,910 | 1,797,138 |
| Commitments and contingencies (Note 8) | - | - |
| Stockholders’ Equity | ||
| Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 800,000 shares authorized; no shares outstanding | — | — |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 1,070,773 shares issued and outstanding at June 30, 2025; 163,093 shares issued and outstanding at December 31, 2024 | 11 | 2 |
| Additional paid in capital | 44,943,081 | 35,287,251 |
| Accumulated deficit | (41,337,573) | (34,578,101) |
| Total Stockholders’ Equity | 3,605,519 | 709,152 |
| Total Liabilities and Stockholders’ Equity | $5,504,429 | $2,506,290 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.